文献速递前列腺癌

20年人群数据:系统TRUS穿刺活检检测临床显著前列腺癌

Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period.
PubMed 文献 · Urology · 2021-06-24

基于丹麦全国前列腺癌登记库1995至2016年数据,评估39,886例首次接受系统TRUS穿刺活检男性的临床显著前列腺癌(csPCa)检出情况。csPCa诊断命中率为40.8%;PSA>20 ng/mL且≥cT2者风险>75%,而cT1且PSA<20 ng/mL者非恶性组织学风险至少58%。系统TRUS活检对可触及肿瘤和高PSA男性诊断准确性高,并非所有男性活检前都需MRI。

要点

  • 系统TRUS活检csPCa总体诊断命中率为40.8%。
  • PSA>20 ng/mL且≥cT2者首次TRUS活检csPCa风险>75%。
  • cT1且PSA<20 ng/mL者非恶性组织学风险至少58%。

核心结论

  • 系统TRUS穿刺活检对可触及肿瘤和高PSA男性的csPCa诊断准确性高。
  • 数据提示并非所有男性在活检前都需要MRI来发现csPCa。

研究设计与样本

  • csPCa定义为任何活检Gleason评分3+4及以上,与PRECISION试验定义一致。

主要发现

  • 首次系统TRUS活检的csPCa诊断命中率为40.8%。
  • PSA>20 ng/mL且≥cT2的男性首次TRUS活检发现csPCa的风险>75%。
  • cT1肿瘤且PSA<20 ng/mL的男性非恶性组织学风险至少58%。

关键数值与推荐

  • csPCa定义:活检Gleason评分3+4及以上。
  • PSA>20 ng/mL且≥cT2:首次TRUS活检csPCa风险>75%。
  • cT1且PSA<20 ng/mL:非恶性组织学风险至少58%。
  • 总体csPCa诊断命中率:40.8%。

临床怎么用

  • 对可触及肿瘤(≥cT2)且PSA>20 ng/mL的男性,系统TRUS活检可高效检出csPCa。
  • 对cT1且PSA<20 ng/mL的男性,需权衡穿刺活检非恶性结果概率较高的情况。
  • 并非所有男性活检前均需MRI即可发现csPCa。

局限性

  • 因缺失信息导致的排除病例数较多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the performance of systematic TRUS-biopsies in a population-based setting to detect clinically significant PCa (csPCa) in combination with age, clinical tumor category (cT), and prostate-specific antigen (PSA) in men referred for the first biopsy. METHODS: We identified all men referred for PCa work-up because of elevated PSA who underwent initial TRUS-biopsies in the nationwide Danish Prostate Cancer Registry (DaPCaR) between January 1st, 1995 and December 31st, 2016, in Denmark. Risk of histologic findings in initial TRUS-biopsies categorized as non-malignant, insignificant PCa, or significant PCa (csPCa). We defined csPCa as any biopsy containing Gleason score 3 + 4 or above as in the PRECISION trial. We assessed risk of csPCa with absolute risk, logistic regression model, and predicted risks. RESULTS AND LIMITATIONS: After exclusions, our cohort included 39,886 men. The diagnostic hit rate for csPCa was 40.8 %. Men with PSA > 20 ng/mL and ≥cT2 harbor a risk >75% for finding csPCa in the first TRUS biopsy-set. Men with cT1 tumors and PSA < 20 ng/mL have a risk of non-malignant histology of at least 58%. Limitations include the high number of exclusions based on missing information. CONCLUSION: The diagnostic accuracy of systematic TRUS-biopsies is high for men with palpable tumors and high PSA. Our data point to the fact that not all men need pre-biopsy MRI to find csPCa.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Kawa SM, Stroomberg HV, Larsen SB, et al. Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period. Urology. 2021. PMID: 34171348. doi:10.1016/j.urology.2021.06.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。